Sonoma pharmaceuticals receives new fda 510(k) clearance with expanded indications for over-the-counter microcyn(r)-based solution

Boulder, co / accesswire / september 17, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the u.s. food and drug administration (fda) for its microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes. per this new clearance, sonoma's microcyn wound care solution can be used for otc management of minor skin abrasions, lacerations and irritations, and intact skin on the face, eyelid and eyelashes.
SNOA Ratings Summary
SNOA Quant Ranking